Accessibility Menu
 
Anebulo Pharmaceuticals logo

Anebulo Pharmaceuticals

(OTC) ANEB

Current Price$0.40
Market Cap$18.35M
Since IPO (2021)-94%
5 YearN/A
1 Year-57%
1 Month-48%

Anebulo Pharmaceuticals Financials at a Glance

Market Cap

$18.35M

Revenue (TTM)

$0.00

Net Income (TTM)

$7.98M

EPS (TTM)

$-0.19

P/E Ratio

-2.32

Dividend

$0.00

Beta (Volatility)

0.46 (Low)

Price

$0.40

Volume

200

Open

$0.40

Previous Close

$0.45

Daily Range

$0.40 - $0.40

52-Week Range

$0.30 - $3.42

ANEB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Anebulo Pharmaceuticals

Industry

Pharmaceuticals

Employees

3

CEO

Richard Anthony Cunningham

Headquarters

Lakeway, TX 78734, US

ANEB Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-70%

Return on Capital

-1%

Return on Assets

-85%

Earnings Yield

-43.10%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$18.35M

Shares Outstanding

40.78M

Volume

200

Short Interest

0.00%

Avg. Volume

70.95K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$9.22M

EBITDA

$8.10M

Operating Cash Flow

$6.35M

Capital Expenditure

$3.00

Free Cash Flow

$6.35M

Cash & ST Invst.

$11.63M

Total Debt

$0.00

Anebulo Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$18.35M

N/A

Market Cap/Employee

$9.18M

N/A

Employees

2

N/A

Net Income

$2.00M

+18.8%

EBITDA

$2.62M

-9.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Net Cash

$9.04M

-39.7%

Accounts Receivable

$56.78K

+84.6%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-84.68%

N/A

Return on Invested Capital

-1.03%

N/A

Free Cash Flow

$1.31M

+6.6%

Operating Cash Flow

$1.31M

+6.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OKYOOKYO Pharma Limited
$1.61+1.26%
CLNNClene Inc.
$6.58+3.62%
ESLAEstrella Immunopharma, Inc.
$1.66-1.20%
TLSATiziana Life Sciences Ltd
$1.30-2.61%

Trending Stocks

Symbol / CompanyPricePrice Chg
EFOIEnergy Focus
$7.63+2.65%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.82+0.06%
PBMPsyence Biomedical
$8.51+0.45%
AALAmerican Airlines Group
$13.37+0.09%

Questions About ANEB

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.